SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

Search

Vetoquinol SA

Geschlossen

BrancheGesundheitswesen

79.6 3.38

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

79.3

Max

79.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

25M

Verkäufe

10M

268M

KGV

Branchendurchschnitt

15.373

66.418

Gewinnspanne

9.734

Angestellte

2,497

EBITDA

252M

301M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+41.57% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-7.1M

928M

Vorheriger Eröffnungskurs

76.22

Vorheriger Schlusskurs

79.6

Nachrichtenstimmung

By Acuity

50%

50%

185 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Vetoquinol SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Apr. 2026, 17:04 UTC

Wichtige Markttreiber

FDA Rejects Replimune's Melanoma Drug for a Second Time

11. Apr. 2026, 00:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Big Yachts, Big Bucks -- Barrons.com

10. Apr. 2026, 21:55 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. Apr. 2026, 21:01 UTC

Ergebnisse

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. Apr. 2026, 20:50 UTC

Market Talk
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

10. Apr. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. Apr. 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. Apr. 2026, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. Apr. 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. Apr. 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. Apr. 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. Apr. 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. Apr. 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10. Apr. 2026, 18:25 UTC

Market Talk
Wichtige Nachrichtenereignisse

Precious Metals Finish With Weekly Gains -- Market Talk

10. Apr. 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10. Apr. 2026, 17:31 UTC

Market Talk
Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10. Apr. 2026, 17:26 UTC

Ergebnisse

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10. Apr. 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10. Apr. 2026, 17:00 UTC

Wichtige Nachrichtenereignisse

Construction Business Taking a Hit From Iran Conflict -- WSJ

10. Apr. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10. Apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10. Apr. 2026, 16:12 UTC

Ergebnisse

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10. Apr. 2026, 16:11 UTC

Ergebnisse

Partners Group: Traditional Programs Contributed $3.3B

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10. Apr. 2026, 16:10 UTC

Ergebnisse

Partners Group 1Q New Client Demand $8.3B

10. Apr. 2026, 16:09 UTC

Ergebnisse

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10. Apr. 2026, 15:54 UTC

Akquisitionen, Fusionen, Übernahmen

Plenitude Completes Acquisition of Acea Energia

10. Apr. 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Vetoquinol SA Prognose

Kursziel

By TipRanks

41.57% Vorteil

12-Monats-Prognose

Durchschnitt 110 EUR  41.57%

Hoch 110 EUR

Tief 110 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vetoquinol SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

72.6 / 75.1Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

185 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat